MX2023012698A - Expansion de linfocitos en un solo recipiente. - Google Patents

Expansion de linfocitos en un solo recipiente.

Info

Publication number
MX2023012698A
MX2023012698A MX2023012698A MX2023012698A MX2023012698A MX 2023012698 A MX2023012698 A MX 2023012698A MX 2023012698 A MX2023012698 A MX 2023012698A MX 2023012698 A MX2023012698 A MX 2023012698A MX 2023012698 A MX2023012698 A MX 2023012698A
Authority
MX
Mexico
Prior art keywords
lymphocytes
single vessel
vessel expansion
population
cells
Prior art date
Application number
MX2023012698A
Other languages
English (en)
Spanish (es)
Inventor
George Coukos
Alexandre Harari
Simone Steiner
Florence Salmon
Original Assignee
Tigen Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigen Pharma Sa filed Critical Tigen Pharma Sa
Publication of MX2023012698A publication Critical patent/MX2023012698A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/13B-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4201Neoantigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00Specific components of cell culture medium
    • C12N2500/98Xeno-free medium and culture conditions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2302Interleukin-2 (IL-2)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20Cytokines; Chemokines
    • C12N2501/23Interleukins [IL]
    • C12N2501/2312Interleukin-12 (IL-12)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00Coculture with; Conditioned medium produced by
    • C12N2502/11Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107B cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MX2023012698A 2021-04-30 2022-04-29 Expansion de linfocitos en un solo recipiente. MX2023012698A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21171565 2021-04-30
PCT/EP2022/061639 WO2022229464A1 (en) 2021-04-30 2022-04-29 Single vessel expansion of lymphocytes

Publications (1)

Publication Number Publication Date
MX2023012698A true MX2023012698A (es) 2024-02-21

Family

ID=76034406

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023012698A MX2023012698A (es) 2021-04-30 2022-04-29 Expansion de linfocitos en un solo recipiente.

Country Status (10)

Country Link
US (1) US20240287454A1 (https=)
EP (1) EP4330380A1 (https=)
JP (1) JP2024517793A (https=)
KR (1) KR20240026905A (https=)
CN (1) CN117321189A (https=)
AU (1) AU2022267777A1 (https=)
BR (1) BR112023022485A2 (https=)
CA (1) CA3214450A1 (https=)
MX (1) MX2023012698A (https=)
WO (1) WO2022229464A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115558641B (zh) * 2022-11-14 2023-05-12 四川新生命干细胞科技股份有限公司 高纯度效应免疫细胞群及其培养方法、试剂组合物和应用
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US20160310584A1 (en) 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
CA3034452A1 (en) 2016-08-21 2018-03-01 Adva Biotechnology Ltd. Bioreactor and methods of use thereof
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
EP3707245A1 (en) * 2017-11-06 2020-09-16 Ludwig Institute for Cancer Research Ltd Method for expansion of lymphocytes
US20230052157A1 (en) 2019-12-12 2023-02-16 Achilles Therapeutics Uk Limited Method for obtaining nucleic acid for sequencing
JP2023510950A (ja) 2020-01-20 2023-03-15 アドヴァ バイオテクノロジー リミテッド バイオリアクタを制御する装置及び方法

Also Published As

Publication number Publication date
CA3214450A1 (en) 2022-11-03
JP2024517793A (ja) 2024-04-23
WO2022229464A1 (en) 2022-11-03
BR112023022485A2 (pt) 2024-01-09
US20240287454A1 (en) 2024-08-29
EP4330380A1 (en) 2024-03-06
AU2022267777A1 (en) 2023-10-05
KR20240026905A (ko) 2024-02-29
CN117321189A (zh) 2023-12-29

Similar Documents

Publication Publication Date Title
MX2023012698A (es) Expansion de linfocitos en un solo recipiente.
MY199870A (en) Microorganism comprising variant lyse and method of l-amino acid production using same
MX2021005021A (es) Proceso para producir celulas t geneticamente modificadas.
Griffiths et al. Unstable cytoplasms in Hawaiian strains of Neurospora intermedia
EP0970701A3 (en) Pellets derived from keratinocytes for use as wound healing substances
NZ597742A (en) Method of producing a polypeptide or virus of interest in a continuous cell culture
DK0418354T3 (da) Fremgangsmåde til in vitro reproduktion og vækst af celler i dyrkningsmedium
WO2004090096A3 (en) Methods for neural differentiation of embryonic stem cells using protease passaging techniques
TW200741001A (en) Method for production of t cell population
WO2022047222A3 (en) Crispr/cas9 multiplex knockout of host cell proteins
WO2021250583A3 (en) 3d culture of mesenchymal lineage precursor or stem cells
IL161873A0 (en) Production of cell suspensions
MX2025000269A (es) Sistema y metodo de cultivo celular multicamara
MX2022010239A (es) Poblaciones de linfocitos t gamma delta ex vivo.
MX2022009958A (es) Cepas de produccion adictas a cargas.
WO2023158750A3 (en) Systems for cell programming and methods thereof
NO20021334D0 (no) Fremgangsmåte for kultivering av celler, en membranmodul, anvendelse av en membranmodul og reaksjonssystem for kultiveringav celler
EP4635527A3 (en) Thymic constructs and uses thereof
WO2024141710A3 (en) An aquaculture system and methods for removing glycerol from the aquaculture system
WO2024030965A3 (en) Reinforced gas-permeable container
DK1048725T3 (da) Fremgangsmåde til fremstilling af pattedyrcellelinjer
WO2024238712A3 (en) Compositions and methods for multiplex engineering of immune cells
WO2024236300A3 (en) System for creating an oxygen gradient across a cell culture insert barrier
HK30105656A2 (en) Methods of preparing chimeric antigen receptor engineered cells
MX2021011375A (es) Cultivos de linfocitos t cd28, composiciones y métodos para su uso.